A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (NCT07011732)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Who can join: Review the eligibility criteria below.
Location: Imaging Endpoints — Scottsdale, Arizona
Age range: 55 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (159 Sites)
Showing the first 25 of 159 sites.
- Imaging Endpoints — Scottsdale, Arizona
- Advanced Research Center (ARC) - Anaheim — Anaheim, California
- Local Institution - 1637 — La Jolla, California
- The Neurology Group — Pomona, California
- Local Institution - 1639 — Torrance, California
- Sunwise Clinical Research — Walnut Creek, California
- Local Institution - 1630 — Colorado Springs, Colorado
- Local Institution - 1622 — Maitland, Florida
- Local Institution - 1631 — Maitland, Florida
- Local Institution - 1666 — Merritt Island, Florida
- Local Institution - 1602 — Miami, Florida
- Local Institution - 1618 — Miami, Florida
- Hope Research Network - Miami — Miami, Florida
- Local Institution - 1604 — Miami, Florida
- Local Institution - 1608 — Ocala, Florida
- Combined Research Orlando (CRO) — Orlando, Florida
- Progressive Medical Research — Port Orange, Florida
- Local Institution - 1655 — Marrero, Louisiana
- CBH Health — Gaithersburg, Maryland
- Local Institution - 1663 — Foxborough, Massachusetts
- Boston Center for Memory — Newton, Massachusetts
- Mayflower Clinical Research — South Dartmouth, Massachusetts
- Elixia MA — Springfield, Massachusetts
- NeuroBehavioral Medicine Group — Bloomfield Hills, Michigan
- Oakland Medical Research — Troy, Michigan
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.